Related Experiment Video

Updated: Jul 12, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

24.8K

Chylomicronemia From GPIHBP1 Autoantibodies Successfully Treated With Rituximab: A Case Report

Jens Lutz1, Malgorzata Dunaj-Kazmierowska1, Sven Arcan1

  • 1Central Rhine Hospital Group, Koblenz, Germany (J.L., M.D., S.A.).

Annals of Internal Medicine
|August 11, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.4K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.2K

Related Experiment Videos

Last Updated: Jul 12, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

24.8K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.4K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.2K

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

Articles linked to this work by shared authors, journal, and citation graph.

High-resolution mapping of osteoblast metabolism and bone matrix turnover in vivo.

Proceedings of the National Academy of Sciences of the United States of America·2026

Discordance between remnant cholesterol and small dense LDL cholesterol obscures interpretation of the results of the PROMINENT trial.

Journal of clinical lipidology·2026

Successful long-term remission of hyperchylomicronemia caused by GPIHBP1 autoantibodies: With insights into antibody epitope effects.

Journal of clinical lipidology·2026

Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison.

Journal of comparative effectiveness research·2026

A Case of Familial Chylomicronemia Syndrome Caused by a Novel Homozygous GPIHBP1 Mutation Successfully Treated with the Selective PPARα Modulator Pemafibrate.

Journal of atherosclerosis and thrombosis·2026

GPIHBP1 on oligodendrocytes binds lipoprotein lipase within the human brain.

Proceedings of the National Academy of Sciences of the United States of America·2026

Interventions to Improve Outpatient Follow-up for Hospitalized Patients With Alcohol Use Disorder : A Systematic Review.

Annals of internal medicine·2026

Association Between Blood Hemoglobin Concentration and Mortality by Age and Sex : A Prospective Cohort Study.

Annals of internal medicine·2026

Tuberculosis.

Annals of internal medicine·2026

Periconception Parental Red Blood Cell Folate, Vitamin B12, and Birth Defects in Offspring : A Prospective Cohort Study.

Annals of internal medicine·2026

In adults with CKM syndrome, finerenone vs. placebo reduced sudden death at a median 2.9 y.

Annals of internal medicine·2026

In HFmrEF or HFrEF, digitalis glycosides reduce a composite of CV death or worsening HF event vs. placebo at a median 36 to 37 mo.

Annals of internal medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us